Quality Improvement Initiative in Immuno-Oncology (QI3)
The BMS Quality Improvement Initiative in Immuno-oncology (QI3) aims to support hospitals and health care providers adapt to the increasing use of I-O agents by making center-specific changes to improve the care of patients on immune checkpoint inhibitors.
The BMS QI3 is open to all health care organizations in Canada. Healthcare professionals employed by or holding a position in a hospital, and actively involved in the delivery of health care to cancer patients treated with immune checkpoint inhibitors are eligible to apply on behalf of their Institution. The list of eligible professionals includes, but is not limited to:
- Nurses and all nursing-affiliated personnel
- Allied health professionals
- Other hospital-based professionals that participate in or who have an interest in improving the delivery of care to cancer patients treated with immune checkpoint inhibitors
Projects requesting up to $50,000 will be considered. Projects must have the potential to transfer knowledge and experience gained, to other disease sites, healthcare teams or hospitals.
Please refer to the Applicant Guide for additional details.
Applicants should download the QI3 Application Form and return the completed form to QI3@bms.com by September 30, 2023. Applications received after the deadline will not be reviewed.
Applicants will be notified of decisions by October 30, 2023.
Caroline Rousseau, PhD
Scientific Advisor, Immuno-Oncology